This study aimed to investigate 
INTRODUCTION
The biodistribution study of tracers in animals is the first step in the development of any radiopharmaceutical that will be subsequently administered in humans. Animal models have been used to develop new drugs to human health, being a useful and effective practice to avoid adverse effects since the 1950s, after the thalidomide scandal when several babies were born with severe deformities in the lower and upper limbs extremities (1) .
Over the past 15 years, there has been a great deal of progress in the development of methods for accurately quantifying nuclear medicine images (2) . Imaging dosimetry becomes an important method because it is a personalized dose distribution analysis and it is non-interventionist. (3) . Dose calculations based on this approach depend on high-quality SPECT (Single Photon Emission Computed Tomography) image quantification, which is generally more reliable than planar methods, but it is also more time and labour-intensive. If done well, however, with appropriate radiation transport methods, one obtains 3D estimates of radiation dose. This is a more sophisticated approach, as it is used in external beam radiotherapy and will eventually allow internal dose planning with radiopharmaceuticals to be employed in the same way (4) .
The analysis of skin cancer has increased over time around the world. Malignant melanoma is less frequent than non-melanoma skin cancer, but is much more aggressive, with a high mortality rate. Early therapy may reduce the use of aggressive therapies such as chemotherapy and radiation therapy, and decrease the risk of developing metastases.
Barboza et al. (5) developed a new radiopharmaceutical, 99m
Tc-Ixolaris, based on a Tissue
Factor inhibitor present at the salivary gland of the tick Ixodes scapularis. The images of this new radiopharmaceutical affinity in organs of interest for melanoma diagnosis in animals and the biodistribution and dosimetric study were performed. Thus, the development of a diagnostic tool increases the possibility of evaluation and follow-up of patients with melanoma, through the understanding of pathophysiological mechanisms.
This study aims to quantify the biodistribution of 99m Tc-Ixolaris in C57BL6 mice, from CT and SPECT images since this is a promising tool in melanoma diagnosis. Through the biodistribution model in mice, this dosimetric study aims to provide data for the future use of this radiopharmaceutical in humans; however it is necessary to carry out the clinical study.
MATERIALS AND METHODS
The procedure applied to animals followed the patterns described for the use of experimental animals, approved by National Counsel of Animal Experimentation Control (CONCEA).
The murine melanoma cell line B16-F10 was induced by intravenous administration in two young male adults C57BL6 mice weighing between 25 and 30 g. In 16 to 17 days after induction, the labelling of Ixolaris, a 15,000 Dalton protein, with two Kunitz-like domains, with 99m Tc was performed and the main quality control tests were executed: radiochemical purity, radionuclide purity, labelling stability and pH.
Radiopharmaceutical
In the direct labelling process of Ixolaris with 99mTc a concentration of 15 μg / mL of stimulating reducing agent (SnCl2 -Sigma Aldrich, USA) sterilized with a 0.22 μm Millipore® filter and 1 μg of Ixolaris was applied.
The test was performed under a pressure test, under a vacuum using the syringe, in laminar flow with autoclaved materials. The Ixolaris and SnCl2 were incubated for ten minutes at room temperature (21°C) and then 37 MBq (1 mCi) was added to the incubation for over ten minutes at room temperature (21°C), ending the marking process. Chromatography on paper, a glass tube containing acetone (ISOFAR®) was used as the mobile phase, capped with a lid, to perform the ascent chromatography; and Whatman #1 paper strips are divided into 4 equal parts, to delimit the tape at the origin and top. An aliquot of the radiopharmaceutical was applied close to the 2 cm mark of origin to start the ascending chromatography (Barboza, 2103) .
Upon arrival of the mobile phase in the line delimiting the top, the paper strips were withdrawn from the chromatography tubes and placed to dry at room temperature. With the dried strips, these were cut into 4 parts in order to identify the location of the labeled molecule along the tape. All pieces of the tapes were placed for radioactive counting on gamma counter (Wizard2, PerkinElmer®).
The stability of the labeling was determined by thin layer chromatography (TLC) using Tc-Ixolaris was administered in mice and serial images of the induced (n=2) and control animal (n=1) were acquired were acquired approximately at 0.5 hour, 1.5 hours, 2.5 hours, 3.5 hours and 24 hours after intravenous injection.
For dosimetric studies, two SPECT cameras (GE Millennium, Xeleris workstation) were used.
Each acquisition was performed for 20 minutes, 32 frames, matrix 128 x 128, and zoom of 4.00.
The OSEM / MLEM iterative reconstruction method with 6 iterations and Butterworth filter 0.5 frequency cut applied, with up to 10 images for each group. SPECT quality control tests were performed during the period between administration and the first image.
Quantification by image
The quantification was performed within regions of interest (ROI) positioned in organs of interest for the time series described above. To anatomically identify the uptake in the organs, SPECT images were fused with CT images held on an Optima 560 PET/CT (GE Healthcare), located in the same hospital.
The number of mean counts and respective associated uncertainties within ROI selection was performed with OsiriX® software and were used for quantification. From the count values, the activities were obtained in time intervals using the volumetric sensitivity determined for Absorbed doses were calculated by MIRD Pamphlet 11 (7) and OLINDA EXM software to compare the results with the ones observed in other studies (8) . Accumulated activities in each organ based on dose factors provided by the software MIRDOSE and Olinda (S factor) and absorbed doses in target organs were calculated. The effective doses were estimated through radiation weighting factors (wR) and tissue or organ weighting factor (wT) provided by ICRP 103
Uncertainty analysis
The activity meter uncertainty of 4.5% was determined from traceability and intercomparison with the National Metrology Laboratory of Ionizing Radiation (LNMRI) in Brazil. The uncertainty for the mice weight used in this study was 0.01%. The uncertainty associated with visual acuity during ROI delimitation was determined performing 10 different measures in the same region; it was noted a 10% variation between scores. Thus, the uncertainty attributed to the absorbed dose was 10% since other uncertainties were considered ten times lower compared to those associated with visual acuity. Tc present in the eluate used for labeling the Ixolaris molecule are described in Table 1 . The limits of the European and American Pharmacopoeias are respectively 0.1% and 0.15%, so the radiochemical purity of the eluate used was 0.1%, an adequate value in comparison to the references. It was concluded that the amount of 99 Mo present in the eluate did not compromise our experiment.
RESULTS AND DISCUSSION

Radiopharmaceutical
The determination of radiochemical impurities resulting from the radiolabelling process of ixolaris with Technetium-99m ( TcO4, this data has been published in Barboza et al, 2015 . The third and final technique for determination of radiochemical purity was thin layer chromatography using silica gel coated fiber sheets (TLC-SG) (n = 6) (table 2), using acetone and 85% methanol as the solvent for determination of the amount of TcO4 -and TcO 2 , respectively. Through this method the radiochemical purity of the 99m Tc-ixolaris was higher than 90% in all the periods (0, 1, 3, 5 and 24h) evaluated.
The larger presence of TcO4 -(2.6 ± 0.53) was observed 24h, as well as the larger presence of TcO2 (5.13  0.72). These data can also be confirmed through the images presented in this article, because another organ of importance for assessing the excessive presence of TcO2, the spleen, no increased uptake is observed in both the experimental and control animals. The presence of colloids formed by the complex 99m Tc-ixolaris from the first hours is low, being implied from the normal biodistribution of this radiopharmaceutical its presence in the liver; and in the lungs when metastasized, due to its ability to bind to the tissue factor expressed in tumor cells. 
Result express mean SD (n = 6).
The table 2 demonstrates the products generated after radiolabeling using SnCl2 as by-products of this process. The presence of both TcO4 -and TcO2 up to 3 h is low and does not compromise the quality of the data found and is not solely responsible for the uptake observed in the liver and lungs.
The concentration of both by-products is high in 24 hours when the radiopharmaceutical will no longer used. The observed radiochemical purity (% Rp) remained above 90% in all observed periods, with the radiopharmaceutical administered within one hour after its production for the experiments performed. Tc -Ixolaris is the ideal to be administered to the patient.
Quantification by image
The three analysed animals were anesthetized and weighed, and the administration of the radiopharmaceutical was performed.
For each animal, five SPECT images related to five different times were acquired to analyse the source organs. The figures 1, 2 and 3 illustrate the images from the animals tested.
Figure 2: SPECT images of the CONTROL animal (29,47 g) for 1.58 h, 3.45 h, 4.40 h, 5.63 h, and 24.26 h after radiopharmaceutical administration (23,14 MBq).
Figure 2 shows that the uptake organs for the CONTROL animal (healthy) were the liver and the bladder. The uptake in the bladder from image 2 is higher than in Image 1, meaning that the maximum uptake occurs between 1.5 h and 3.5 h. In Image 3, a subsequent decrease in liver uptake can be seen, and the images 4 and 5 show biological excretion associated with physical decay. From the activity versus time curve of the CONTROL animal, Figure 5 , it can be observed that the liver uptake is approximately 1.6 times greater than bladder elimination and, the liver curve follows the theoretical pattern associated with the biological elimination and physical decay. The bladder curve shows the moment of maximum uptake in second point. Later, the physical and biological decay can be seen. 
Figure 6: Uptake organ activity versus time curve (liver, lung and bladder) of INDUCED A animal
For INDUCED B animal, Figure 7 , it can be observed that the liver uptake is approximately 3.8 times greater than the lung uptake and 1.4 times greater than the elimination by urinary bladder. It can be also seen that the liver curve follows the theoretical pattern combining the biological elimination and physical decay. The lung curve shows the time of maximum uptake between the first and the third point; later it can be seen the physical and biological decay.
Figure 7: Uptake organs activity versus time curve (liver, lung and bladder) for INDUCED B animal
Because there is no published reference organ mass for mice, the average of animal organ mass used in this work was considered and are presented in Table 3 . In this work was used the metabolic factor of 7.02, in addition to mass flow factors frequently used for imaging dosimetric calculations. The mass factors applied were 0.51 for liver, lung and 1.51 to 1.64 for the bladder, which carry a metabolic mass and a correction factor of 3.58
for the liver, 10.60 for lung and 11.51 to the bladder.
The results obtained of accumulated activities (Ã) which represents an integral time of curvature, that is, an area under the curve, are shown in Table 4 . Thus, obtaining the total of disintegrations that occur over time in a region of interest in animal. The accumulated activities corrected (Ãcorrected) is the same information, but in human estimate from the animal.
The residences times (τ), for each human organ estimated from each animal are shown in Table 4 . It can be seen that the organs that had higher residence times were the liver and lung, in ascending order, and sometimes the bladder. So, these organs have higher total number of disintegrations that occurred for a given integration time per unit of activity initially administered.
The differences observed in INDUCED data, among the accumulated activity values, corrected cumulative activity and residence time for the bladder are due to the different acquisition times for the images whether urinary excretion occurred or not, with no possibility of control during the experiment.
Absorbed doses in the target organs due to source organs (liver, lung and bladder) in humans were calculated from the S factors for 99m
Tc by the MIRD Pamphlet 11 publication and Olinda EXM software, which are shown in Table 5 .
The results for the two methods are very similar for all organs, while some S factors are set often complementary in each method. Thus, by using both, it was possible to estimate the absorbed dose to a larger number of organs studied.
As the comparison between different procedures and even risk estimation are carried out through effective dose values, these were calculated using the radiation weighting factor (wR) for photon and tissue weighting factors (wT), both established in (9) .
According to the absorbed doses calculated from the S factors provided by the software MIRDOSE, the effective dose observed in the human body for the developed It is known that for medical exposures there is no dose limitation. However, reference levels, i.e.
guideline levels, are used in medical imaging to indicate whether under routine conditions the dose for the patient or the amount of radiopharmaceutical administered in a specific examination is abnormally high or too low for the procedure. Tc-ixolaris of C57BL6 mice induced with the murine melanoma B16-F10 cells was carried out in order to determine their biokinetic model.
To obtain the absorbed doses resulting from the use of the new radiopharmaceutical, a dosimetry method of imaging and the translation method of mice to humans were used, considering the mass and metabolic differences between the two species. h). Given the residence times in human organs extrapolated from the information acquired in mice, it was concluded that the organs which had a higher total number of disintegrations (for a given integration time for initially given unit of activity) were the liver, lungs and, sometimes, the bladder. Consequently, the organs that received higher absorbed doses were the liver (7.45 ± 0.74 mGy), lungs (8.26 ± 0.83 mGy), bladder (24.65 ± 2.46 mGy) and the target organ, uterus (2.69 ± 0.27 mGy).
It is worth noticing the importance of considering the mass differences between mice and humans as well as the metabolic differences, since it leads to a large increase in the estimated dose.
Not considering these differences is the same as ensuring that, despite having different organs sizes in the body, rats and humans have the same metabolic rate, which is not true. In this work, from the man reference data provided by the ICRP 89 and from the data of mice experimentally calculated, we used the metabolic factor of 7.02, in addition to mass flow factors frequently used for imaging dosimetric calculations. The mass factors applied were 0.51 for liver, lung and 1.51 to 1.64 for the bladder, which carry a metabolic mass and a correction factor of 3.58 for the liver, 10.60 for lung and 11.51 to the bladder.
Absorbed doses in radiosensitive organs such as bone marrow and kidney were, respectively, 0.91 ± 0.10 mGy and 1.17 ± 0.13 mGy, suggesting that this radiopharmaceutical is safe.
Therefore, for humans with melanoma in which 99m
Tc-Ixolaris could be administered, the estimated effective dose would be 4.3 ± 0.5 mSv, value similar to other diagnostic techniques with the same radionuclide, ranging from 0.6 mSv to 4.8 mSv.
CONCLUSION
It can be concluded that the beginning of a clinical phase with human trials is safe, since both the estimated absorbed dose in critical organs and the effective doses were in agreement to the ones observed nowadays in other well-established methods.
